Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01823835 | A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer | terminated | Phase 1 / Phase 2 | 152 | Genentech, Inc.INDUSTRY | 4 | Jun 18, 2021 | clinicaltrials |
| NCT03983395 | Study of ISB 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer | terminated | Phase 1 / Phase 2 | 1 | Ichnos Sciences SAINDUSTRY | 1 | May 24, 2021 |
| clinicaltrials |
| NCT02936206 | Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant. | terminated | Phase 1 | 2 | Icahn School of Medicine at Mount SinaiOTHER | 1 | May 19, 2021 | clinicaltrials |
| NCT03134638 | A Study of SY-1365 in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 | 107 | Syros PharmaceuticalsINDUSTRY | 3 | Mar 9, 2021 | clinicaltrials |
| NCT03125200 | Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression | terminated | Phase 1 | 21 | ADC Therapeutics S.A.INDUSTRY | 2 | Feb 1, 2021 | clinicaltrials |
| NCT02698176 | A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006) | terminated | Phase 1 | 13 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jan 27, 2021 | clinicaltrials |
| NCT03429101 | A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer | terminated | Phase 1 | 6 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Jan 15, 2021 | clinicaltrials |
| NCT03292536 | Merestinib on Bone Metastases in Subjects With Breast Cancer | terminated | Phase 1 | 2 | University of UtahOTHER | 1 | Jan 8, 2021 | clinicaltrials |
| NCT01495247 | Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer | terminated | Phase 1 / Phase 2 | 18 | Novartis PharmaceuticalsINDUSTRY | 2 | Dec 8, 2020 | clinicaltrials |
| NCT02993094 | Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Advanced Triple Negative Breast Cancer | terminated | Phase 1 / Phase 2 | 31 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | Nov 30, 2020 | clinicaltrials |
| NCT03292172 | A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer | terminated | Phase 1 | 36 | Hoffmann-La RocheINDUSTRY | 5 | Nov 6, 2020 | clinicaltrials |
| NCT02781805 | Pilot Study of Bisphosphonates for Breast Cancer | terminated | Phase 1 | 6 | University of Wisconsin, MadisonOTHER | 1 | Oct 22, 2020 | clinicaltrials |
| NCT02095210 | HER2 PET Imaging in Breast Cancer Patients Using [68GA]ABY-025 | terminated | Phase 1 | 2 | Dorte NielsenOTHER | 1 | Oct 5, 2020 | clinicaltrials |
| NCT01697293 | PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer | terminated | Phase 1 / Phase 2 | 34 | Prescient Therapeutics, Ltd.INDUSTRY | 1 | Sep 24, 2020 | clinicaltrials |
| NCT03957096 | A Safety Study of SGN-CD47M in Patients With Solid Tumors | terminated | Phase 1 | 16 | Seagen Inc.INDUSTRY | 1 | Sep 17, 2020 | clinicaltrials |
| NCT01249443 | Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection | terminated | Phase 1 | 17 | AIDS Malignancy ConsortiumNETWORK | 1 | Jul 29, 2020 | clinicaltrials |
| NCT00075673 | Vinorelbine and Celecoxib in Treating Women With Relapsed or Metastatic Breast Cancer | terminated | Phase 1 | 6 | Case Comprehensive Cancer CenterOTHER | 1 | Jul 27, 2020 | clinicaltrials |
| NCT00905021 | Exemestane With Sunitinib (SUTENT®) in Metastatic Breast Cancer(EXTENT) | terminated | Phase 1 / Phase 2 | 4 | Baylor Breast Care CenterOTHER | 1 | Jul 24, 2020 | clinicaltrials |
| NCT00003086 | Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer | terminated | Phase 1 / Phase 2 | 12 | Louisiana State University Health Sciences Center ShreveportOTHER | 1 | Jul 14, 2020 | clinicaltrials |
| NCT03343613 | A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors | terminated | Phase 1 | 60 | Eli Lilly and CompanyINDUSTRY | 6 | Jun 9, 2020 | clinicaltrials |
| NCT02512237 | A Dose-escalation Study of ARX788, IV Administered in Subjects With Advanced Cancers With HER2 Expression | terminated | Phase 1 | 9 | Zhejiang Medicine Co., Ltd.INDUSTRY | 2 | Jun 5, 2020 | clinicaltrials |
| NCT00090480 | Vaccine Treatment for Advanced Breast Cancer | terminated | Phase 1 / Phase 2 | 3 | NewLink Genetics CorporationINDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT00739609 | IDO Inhibitor Study for Relapsed or Refractory Solid Tumors(D-1MT) | terminated | Phase 1 | 17 | NewLink Genetics CorporationINDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT01532960 | Pilot Study of a Breast Cancer Vaccine Plus Poly-ICLC for Breast Cancer(Breast 41) | terminated | Phase 1 | 11 | Craig L Slingluff, JrOTHER | 1 | May 8, 2020 | clinicaltrials |
| NCT02576665 | A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6) | terminated | Phase 1 | 21 | Tocagen Inc.INDUSTRY | 1 | Feb 7, 2020 | clinicaltrials |
| NCT00616122 | Sunitinib, Cyclophosphamide, and Methotrexate in Treating Patients With Metastatic Breast Cancer | terminated | Phase 1 / Phase 2 | 32 | University of California, San FranciscoOTHER | 1 | Jan 13, 2020 | clinicaltrials |
| NCT02003092 | RX-5902 Treatment of Subjects With Triple Negative Breast Cancer | terminated | Phase 1 / Phase 2 | 18 | Rexahn Pharmaceuticals, Inc.INDUSTRY | 1 | Jan 6, 2020 | clinicaltrials |
| NCT00005655 | Combination Therapy of Interleukin-12 and Interleukin-2 to Treat Advanced Cancer | terminated | Phase 1 | 39 | National Cancer Institute (NCI)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT00140140 | A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer | terminated | Phase 1 / Phase 2 | 16 | CelgeneINDUSTRY | 1 | Nov 26, 2019 | clinicaltrials |
| NCT00531271 | ABI-008 Trial in Patients With Metastatic Breast Cancer | terminated | Phase 1 / Phase 2 | 85 | CelgeneINDUSTRY | 1 | Nov 14, 2019 | clinicaltrials |
| NCT01118975 | GCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers | terminated | Phase 1 / Phase 2 | 12 | University of Maryland, BaltimoreOTHER | 1 | Nov 13, 2019 | clinicaltrials |
| NCT02318901 | Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer(PembroMab) | terminated | Phase 1 / Phase 2 | 16 | Western Regional Medical CenterOTHER | 1 | Oct 21, 2019 | clinicaltrials |
| NCT02582801 | Clinical Research of 18F-Alfatide Ⅱ PET/CT in Breast Cancer | terminated | Phase 1 | 46 | Jiang WuOTHER | 1 | Sep 27, 2019 | clinicaltrials |
| NCT00972023 | DHEA in Treating Women Undergoing Surgery for Stage I, Stage II, or Stage III Breast Cancer | terminated | Phase 1 | 1 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Sep 17, 2019 | clinicaltrials |
| NCT02983604 | GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer | terminated | Phase 1 / Phase 2 | 14 | Gilead SciencesINDUSTRY | 1 | Aug 7, 2019 | clinicaltrials |
| NCT02952989 | A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors | terminated | Phase 1 | 47 | Seagen Inc.INDUSTRY | 1 | Jul 19, 2019 | clinicaltrials |
| NCT03062007 | Open-label Study of Safety, Tolerability and Pharmacokinetics of Multiple Doses of BI-CON-02 in Patients With HER2-positive Metastatic Breast Cancer, Previously Treated With Trastuzumab | terminated | Phase 1 | 6 | Biointegrator LLCINDUSTRY | 1 | Jul 16, 2019 | clinicaltrials |
| NCT02153905 | T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive | terminated | Phase 1 / Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Jun 17, 2019 | clinicaltrials |
| NCT00607841 | A Study of Ispinesib in Metastatic Breast Cancer | terminated | Phase 1 | 16 | CytokineticsINDUSTRY | 1 | May 6, 2019 | clinicaltrials |
| NCT02136927 | Bioavailability Study of SPARC1210 and Reference1210 in Subjects With Metastatic Breast Cancer | terminated | Phase 1 | 33 | Sun Pharma Advanced Research Company LimitedINDUSTRY | 1 | May 3, 2019 | clinicaltrials |
| NCT02078752 | A Study Of PF-06647263 In Patients With Advanced Solid Tumors | terminated | Phase 1 | 60 | PfizerINDUSTRY | 1 | Apr 29, 2019 | clinicaltrials |
| NCT02384746 | Phase I Study of the Combination of MLN9708 and Fulvestrant(Millennium) | terminated | Phase 1 | 9 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Apr 29, 2019 | clinicaltrials |
| NCT02658084 | Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer | terminated | Phase 1 / Phase 2 | 2 | University of MiamiOTHER | 1 | Apr 17, 2019 | clinicaltrials |
| NCT02129205 | A Dose Escalation Study of PF-06650808 in Patients With Advanced Solid Tumors | terminated | Phase 1 | 40 | PfizerINDUSTRY | 1 | Mar 29, 2019 | clinicaltrials |
| NCT00063934 | Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer | terminated | Phase 1 / Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Mar 5, 2019 | clinicaltrials |
| NCT02067884 | Contrast Enhanced Ultrasound and Shear Wave Elastography in Measuring Response in Patients With Breast Cancer Receiving Chemotherapy Before Surgery | terminated | Phase 1 | 34 | University of Southern CaliforniaOTHER | 1 | Jan 25, 2019 | clinicaltrials |
| NCT01891669 | A Study Of PF-06263507 In Patients With Advanced Solid Tumors | terminated | Phase 1 | 26 | PfizerINDUSTRY | 1 | Jan 9, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Jun 18, 2021source: clinicaltrials